BCT301 / Peking University Third Hospital - LARVOL DELTA

Clinical Study of BCT301 Cell Injection Therapy for Refractory Autoimmune Diseases (clinicaltrials.gov) - P1 | N=10 | Recruiting | Sponsor: Peking University Third Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • ANCA Vasculitis • Genetic Disorders • Hematological Disorders • Immunology • Inflammatory Arthritis • Lupus • Myositis • Scleroderma • Sjogren's Syndrome • Systemic Lupus Erythematosus • Systemic Sclerosis • Vasculitis • CD19

BCT301 in Treating Refractory/Recurrent IgG4-related Disease (clinicaltrials.gov) - P=N/A | N=6 | Not yet recruiting | Sponsor: Peking University Third Hospital

New trial • Inflammation • CD19